Recent Quotes (30 days)

You have no recent quotes
chg | %

AstraZeneca plc news

   Watch this stock
Showing stories 1 - 10 of about 48   

Articles published

AZN 4,109.50 -33.50 (-0.81%)
price chart
Amylin Said to Attract Interest From Pfizer, AstraZeneca
AstraZeneca Plc, the U.K.'s second-biggest drugmaker, shouldn't get a further reduction in an antitrust fine of 52.5 million euros ($67.5 million), an adviser to the European Union's highest court said.
Did Say On Pay Cost A CEO His Job?
Likewise, at British drug maker AstraZeneca, CEO David Brennan announced two weeks ago that he would resign on June 1. AstraZeneca, hit by competition from generic drug manufacturers and the failure of several drugs in development, has seen shares ...
Boards wake up to a shareholder spring
Two weeks ago David Brennan, chief executive of AstraZeneca, bowed to pressure from the pharmaceutical group's top shareholders and stepped down at the annual meeting.
EU to push for binding investor pay votes
Shareholders in Europe's listed companies will be given a binding vote on pay while those who invest in banks will gain powers to set a cap on bonus levels, under plans being drawn up by senior EU officials.
Life assurance bonds can keep the taxman at bay
The taxman is always keen to take his share of everything, from your income to the wealth you leave your family, so finding ways to reduce your tax bill is a rewarding activity.
Drugmakers see $33bn bout of M&A activity
While the appetite for “mega mergers” has dulled, several midsize companies including Shire and Biogen Idec are regularly cited as potential targets.
US to Seek New Uses for Abandoned Drugs
The U.S. government said Thursday it will work with large pharmaceutical companies to try to find new uses for once-promising drugs that have been cast aside by the industry.
Moss quits after pay revolt at Aviva
Mr Moss is the third high-profile UK chief executive to fall victim to investor anger, following the departures of Sly Bailey from Trinity Mirror and David Brennan from AstraZeneca. But the terms of Mr Moss's exit drew criticism after Aviva last week ...
Aviva CEO Pressed to Step Down After Meeting Revolt  Bloomberg
Where can investors find shelter from the volatility storm?
Similarly, AstraZeneca fell by 665p but it is yielding a very attractive 6.5pc. Mr McDermott tipped Neil Woodford's Invesco Perpetual High Income fund but said equities were not the only route to income.
Heart Patients May Face a New Drug Dilemma
That compares with the wholesale cost of $6.44 a day for brand-name Plavix and similar prices for Eli Lilly LLY -2.52 % & Co.'s Effient, at $6.38 a day, and AstraZeneca PLC's Brilinta, which lists for $7.68 per day. Doctors hope the lower price for ...